Dangerous Drug: Pramlintide Acetate(pram’ lin tyde)
Symlin
PREGNANCY CATEGORY C
Drug Classes
Amylinomimetic
Antidiabetic
Therapeutic Actions
A synthetic analogue of human amylin, a hormone produced by the beta cells in the pancreas that helps to control glucose levels in the postprandial period; modulates gastric emptying, causes a feeling of fullness or satiety, prevents the postprandial rise in serum glucagon levels all leading to lower serum glucose levels.
Indications
Adjunct treatment in patients with type 1 diabetes who use mealtime insulin and who have failed to achieve desired glucose control despite optimal insulin therapy
Adjunct treatment in type 2 diabetes patients who use mealtime insulin and who have failed to achieve desired glucose control despite optimal insulin therapy with or without a concurrent sulfonylurea or metformin
Contraindications and Cautions
Contraindicated with known hypersensitivity to pramlintide or any of its components, gastroparesis, hypoglycemia unawareness.
Use cautiously with pregnancy, lactation.
Available Forms
Solution for injection—1.5 mg/1.5 mL, 2.7 mg/2.7 mL
Dosages
Adults
Type 2 diabetes: Initially, 60 mcg by subcutaneous injection immediately prior to major meals. Dose may be increased to 120 mcg
if needed and tolerated. Dosage of oral drugs and insulins will need to be reduced, usually by 50% based on patient response.
Type 1 diabetes: Initially, 15 mcg by subcutaneous injection immediately before major meals, titrate at 15 mcg increments to a maintenance dose of 30 or 60 mcg as tolerated. Dosage of insulins will need to be reduced by 50% and the patient must be monitored closely to achieve optimal glucose control.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
